Overview

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Status:
Recruiting

Trial end date:
2022-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Plexxikon

Treatments:

Carboplatin